You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (28) |
Back to Search
Cyp2d6*10 polymorphisms on tamoxifen metabolism in breast cancer patients
- In: Posters G - Pharmacokinetics (PK), Pharmacodynamics (PD) and Systems Pharmacology
- At: PSWC, Melbourne (Australia) (2014)
- Type: Poster
- Poster code: PG-037
- By: PAO, Li-Heng (Chang Gung University of Science and Technology, Research Center for Industry of Human Ecology, Taoyuan, China Taiwan)
- Co-author(s): Ho, Ya-Ting (School of Pharmacy, National Defense Medical Center, Taipei, China Taiwan)
Lo, Chia-Yi (Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, China Taiwan)
Dai, Ming-Shen (Department of Hematology and Oncology, Tri-Service General Hospital, Taipei, China Taiwan)
Shih, Jui-Hu (Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, China Taiwan) - Abstract:
Background: Tamoxifen has been the gold standard for reducing the risk of recurrence and mortality in adjuvant endocrine therapy. The active metabolites of tamoxifen, 4-hydroxytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen), have been considered to have 100-fold greater affinity for estrogen receptors than the parent drug. Several study..
The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026